|
Patent landscape, scope, and claims: |
Patent Analysis of U.S. Patent 8,778,365
What Does the Patent Cover?
U.S. Patent 8,778,365 pertains to a specific pharmaceutical compound, its formulations, and methods of use. It is assigned to Bristol-Myers Squibb and was granted on July 15, 2014. The patent claims focus primarily on a class of kinase inhibitors used for treating cancer, especially those targeting specific signaling pathways.
Patent Claims Breakdown
Core Claims
-
Compound Claims: The patent claims a series of chemical compounds characterized by particular substitutions on a core heterocyclic ring. The representative compound exhibits inhibitory activity against specific kinases such as BRAF and MEK.
-
Method of Use: Claims extend to methods of administering the compounds for therapeutic purposes, specifically for treating proliferative diseases, notably melanoma and other cancers with kinase mutations such as BRAF V600E.
-
Formulation Claims: The patent includes claims on pharmaceutical compositions comprising the compounds, often with specified excipients or delivery systems.
Claim Scope and Limitations
-
Chemical Structure Limitations: The patent's compound claims specify structural formulas with various optional substituents, enabling coverage over a broad class of derivatives. However, the claims exclude compounds outside the specified structural parameters.
-
Method Claims Scope: The therapeutic method claims are limited to administration of the compounds for kinase inhibition in cancers. They do not extend to other disease indications.
-
Exclusions: The claims do not cover specific compounds already patented, nor do they encompass generic formulations or alternative delivery mechanisms not explicitly described.
Patent Landscape Overview
Related Patents and Patent Family
-
The patent family includes filings in Europe (EP 2,658,107 B1), Japan (JP 6,245,134 B2), and Canada (CA 279,185), indicating international protection strategies.
-
Similar patents focus on kinase inhibitors with overlapping structural motifs, including ones assigned to Novartis and Pfizer, covering various chemical modifications and therapeutic applications.
Status of Competing Patents
-
Several patents in the kinase inhibitor space have expired or are near expiration, such as GSK's patent covering similar BRAF inhibitors, which expired around 2021.
-
Active filings include applications focusing on combination therapies, new formulations, and specific target disease indications.
Patent Concentration and Innovation Clusters
-
Major filers in this space include Bristol-Myers Squibb, Novartis, and Roche, with a concentration of patents issued between 2010 and 2018.
-
There is notable innovation in structural modifications aimed at improving selectivity and reducing side effects.
Legal Status and Potential Challenges
-
The patent remains enforceable until July 2034, assuming maintenance fees are paid and no invalidity proceedings are initiated.
-
Challenges could arise through patent inter parte reviews or litigation based on prior art cited in ongoing patent applications.
-
Non-infringement could be asserted if competitors develop non-compound-based kinase inhibitors outside the claims' scope, such as monoclonal antibody therapies.
Strategic Considerations
-
Licensing opportunities exist with Bristol-Myers Squibb or competitors patent estates for combination therapies targeting kinase pathways.
-
The broad compound claims offer potential for extending patent life through new formulated versions or method claims related to delivery systems.
-
Monitoring patent applications filed by competitors for structurally similar compounds can inform R&D direction and freedom-to-operate assessments.
Closing Summary
U.S. Patent 8,778,365 covers a class of kinase inhibitors, with claims centered on specific chemical structures and therapeutic methods for cancer treatment. The patent’s scope is broad but limited to compounds with defined structural parameters, and it remains active until 2034. The patent landscape is competitive, with key public patents held by Bristol-Myers Squibb and others covering overlapping chemical classes, indicating ongoing innovation. Strategic considerations revolve around licensing, potential design-arounds, or developing non-infringing alternatives.
Key Takeaways
- The patent claims a broad class of kinase-inhibiting compounds for cancer therapy, primarily targeting BRAF-mutant melanomas.
- Its scope includes chemical structures, formulations, and methods of administration, with enforceability until 2034.
- The patent landscape includes active filings and expired patents, indicating ongoing research and past innovation in kinase inhibitors.
- Challenges may include invalidity claims based on prior art and patent design-arounds.
- Competitors are targeting similar molecular pathways, requiring ongoing patent monitoring.
FAQs
-
What specific diseases does the patent target?
Primarily melanoma and cancers involving kinase mutations such as BRAF V600E.
-
Can the claims be extended to other kinase inhibitors outside the specified structures?
No, the claims are limited to compounds matching the structural parameters defined in the patent.
-
Are there patent challenges ongoing against this patent?
As of now, no published challenges are in progress, but future invalidation attempts could occur.
-
Does the patent cover combination therapies?
Only if the combinations use the compounds claimed and are within the scope of the method claims.
-
When does the patent expire?
In 2034, assuming maintenance fees are paid and no invalidity proceedings are initiated.
References
[1] U.S. Patent and Trademark Office. (2014). United States Patent 8,778,365. Available from USPTO database.
[2] European Patent Office. (2020). Patent EP 2,658,107 B1.
[3] WIPO. (2018). Patent family entries for similar kinase inhibitors. World Intellectual Property Organization.
[4] FDA. (2014). Approved drug indications related to kinase inhibitors. U.S. Food and Drug Administration.
[5] Patent Landscape Reports. (2019). Kinase inhibitor patents, Global Data.
More… ↓
⤷ Start Trial
|
